AstraZeneca's revelation in its fourth-quarter results update - that it had decided to build a new $360 million manufacturing facility in Ireland, rather than its home ter
Sales of AstraZeneca's COVID-19 vaccine dwindled to almost nothing in the fourth quarter of 2022, contributing to a weaker-than-expected performance for the group.
Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure (CHF) w
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
